Zelira Therapeutics (ASX:ZLD) 3-Year RORE % : -5.79% (As of Jun. 2025)

Zelira Therapeutics  (ASX:ZLD) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.

Zelira Therapeutics 3-Year RORE % Related Terms

The historical data trend for Zelira Therapeutics's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics 3-Year RORE % Chart

Zelira Therapeutics Annual Data
	Trend	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23	Jun24	Jun25
3-Year RORE %		Get a 7-Day Free Trial					12.80	2.11	-21.49	31.58	-5.79

Zelira Therapeutics Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25
3-Year RORE %	Get a 7-Day Free Trial															-21.49	29.74	31.58	-14.01	-5.79

ASX:ZLD vs MTNB, SXTP, GLMD: 3-Year RORE % Comparison

For the Biotechnology subindustry, Zelira Therapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zelira Therapeutics 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Zelira Therapeutics's 3-Year RORE % falls into.

Zelira Therapeutics 3-Year RORE % Calculation

Zelira Therapeutics's 3-Year RORE % for the quarter that ended in Jun. 2025 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2025 and 3-year before.

Zelira Therapeutics Business Description